PDCD1 and cancer: In a large retrospective study investigating patients with various cancers treated with anti–PD-1 drugs, there were clinical benefits identified as remarkably higher objective response rate (ORR) (30.4% vs. 12.7%), notably prolonged median progression-free survival (PFS) (17.6 months vs. 3.0 months) and overall survival (OS) (48.7 months vs. 10.7 months) in patients with irAEs than in those without irAEs (97).